TSX gains back after eight-day rally snapped
Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics (NASDAQ:NKTR), sold 1,721 shares of common stock on September 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed in multiple transactions with prices ranging from $32.43 to $35.69, totaling $57,692.
The filing indicates that these transactions were executed pursuant to a Rule 10b5-1 trading plan. Following the reported transactions, Zalevsky directly owns 17,462 shares of Nektar Therapeutics , which currently has a market capitalization of $837.58 million. The stock has shown remarkable performance, delivering a 236.6% return over the past six months. For deeper insights into NKTR’s valuation and 15+ additional exclusive ProTips, visit InvestingPro.
In other recent news, Nektar Therapeutics reported a significant earnings miss for the second quarter of 2025. The company’s earnings per share were -$2.78, a stark contrast to the projected -$0.20, marking a 1,290% deviation from expectations. However, Nektar’s revenue exceeded forecasts, reaching $11.17 million compared to the anticipated $9.74 million. In related developments, Nektar’s stock saw a substantial rise after Sanofi released underwhelming clinical trial results for its atopic dermatitis treatment, amlitelimab. The disappointing data from Sanofi’s Phase 3 COAST-1 trial have been seen as potentially beneficial for Nektar’s competitive positioning. Piper Sandler analyst Yasmeen Rahimi maintained an overweight rating on Nektar, highlighting the competitive advantage of Nektar’s drug REZPEG. Rahimi emphasized REZPEG’s differentiated profile, suggesting a promising year ahead for Nektar in the inflammatory diseases market. These recent developments have drawn significant attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.